VERAXA Biotech (NASDAQ: VRXA) is expanding its use of human-relevant preclinical testing methods across its antibody-based cancer drug development programs, aiming to improve the clinical relevance of research findings while reducing animal testing. The company is implementing New Approach Methodologies (NAMs), including three-dimensional tumor spheroid models and patient-derived tumor models, in support of its BiTAC(R) T-cell engagers, antibody-drug conjugates and bispecific antibody-drug conjugates.
VERAXA reported that its lead BiTAC T-cell engager demonstrated selective, potent T-cell-mediated tumor-cell killing across 10 patient-derived non-small cell lung cancer models, while relevant controls showed minimal activity. The ex vivo study required approximately 10 mice, compared with an estimated 200 or more for comparable in vivo efficacy studies, according to the company. The findings support VERAXA’s dual-targeting approach, which is designed to direct immune activity toward cancer cells expressing two selected targets, and its broader strategy of using human-relevant models in preclinical research.
The move matters because it could accelerate drug development by providing more predictive data before human trials, potentially reducing failure rates and costs. It also addresses ethical concerns about animal testing, aligning with regulatory trends favoring human-relevant models. For investors, the update signals progress in VERAXA’s pipeline and its commitment to innovative research methodologies.
To view the full article, visit https://ibn.fm/jZrd2. For regular updates about VERAXA Biotech, visit https://investors.veraxa.com. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
About InvestorWire: InvestorWire is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
